Loading
A phase 2/3 trial of pembrolizumab in lung cancer, run by Canadian Cancer Trials Group, active but no longer recruiting.
Study of CTDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer is a phase 2/3, randomised interventional study registered as NCT04093167 by Canadian Cancer Trials Group, with a registry enrolment figure of 53 participants, started 2020-05-26 and due to reach its primary completion in 2026-12-31. Interventions recorded: Pembrolizumab. Conditions listed: Lung Cancer. Primary outcome: Stage 1: Concordance rate between molecular response and radiologic response; Stage 2: Phase II Progression-Free Survival (PFS); Stage 2: Phase III Overall Survival. Lung eligibility wording from the registry: "* Histologically or cytologically confirmed metastatic NSCLC". Sites: Canada, United States. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Lung cancer trials open today (registry snapshot), Lung cancer (all types), Pembrolizumab, Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Pembrolizumab, Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Lung cancer (all types), Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Pembrolizumab, Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Canadian Cancer Trials Group (CCTG), Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Pembrolizumab, Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Lung cancer (all types), Pembrolizumab, Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Pembrolizumab, Immune checkpoint inhibitors and the tag lung-deep-dive.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/